This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2no9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2no9.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2no9.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2no9| PDB=2no9 | SCENE= }}
{{STRUCTURE_2no9| PDB=2no9 | SCENE= }}
-
'''The structure of deoxycytidine kinase complexed with troxacitabine and ADP.'''
+
===The structure of deoxycytidine kinase complexed with troxacitabine and ADP.===
-
==Overview==
+
<!--
-
L-nucleoside analogs represent an important class of small molecules for treating both viral infections and cancers. These pro-drugs achieve pharmacological activity only after enzyme-catalyzed conversion to their tri-phosphorylated forms. Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent. The first step in activating these agents is catalyzed by dCK. Our studies reveal how dCK, which normally catalyzes phosphorylation of the natural D-nucleosides, can efficiently phosphorylate substrates with non-physiologic chirality. The capability of dCK to phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of both the enzyme and the substrates themselves. First, the nucleoside-binding site tolerates substrates with different chiral configurations by maintaining virtually all of the protein-ligand interactions responsible for productive substrate positioning. Second, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformational flexibility allows the L- and D-enantiomeric forms to adopt similar shapes when bound to the enzyme. This is the first analysis of the structural basis for activation of L-nucleoside analogs, providing further impetus for discovery and clinical development of new agents in this molecular class.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17158155}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17158155 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17158155}}
==About this Structure==
==About this Structure==
Line 31: Line 35:
[[Category: L-dc]]
[[Category: L-dc]]
[[Category: Troxacitabine]]
[[Category: Troxacitabine]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 09:41:57 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 05:12:22 2008''

Revision as of 02:12, 29 July 2008

Image:2no9.png

Template:STRUCTURE 2no9

The structure of deoxycytidine kinase complexed with troxacitabine and ADP.

Template:ABSTRACT PUBMED 17158155

About this Structure

2NO9 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase., Sabini E, Hazra S, Konrad M, Burley SK, Lavie A, Nucleic Acids Res. 2007;35(1):186-92. Epub 2006 Dec 7. PMID:17158155

Page seeded by OCA on Tue Jul 29 05:12:22 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2no9"
Personal tools